[go: up one dir, main page]

ATE325135T1 - 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung - Google Patents

2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung

Info

Publication number
ATE325135T1
ATE325135T1 AT02712915T AT02712915T ATE325135T1 AT E325135 T1 ATE325135 T1 AT E325135T1 AT 02712915 T AT02712915 T AT 02712915T AT 02712915 T AT02712915 T AT 02712915T AT E325135 T1 ATE325135 T1 AT E325135T1
Authority
AT
Austria
Prior art keywords
alkylated
drug
neuromuscular block
reversal agent
cyclodextrine derivatives
Prior art date
Application number
AT02712915T
Other languages
English (en)
Inventor
Mingqiang Zhang
Gary Tarver
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE325135T1 publication Critical patent/ATE325135T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02712915T 2001-02-14 2002-02-14 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung ATE325135T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01200535 2001-02-14

Publications (1)

Publication Number Publication Date
ATE325135T1 true ATE325135T1 (de) 2006-06-15

Family

ID=8179895

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02712915T ATE325135T1 (de) 2001-02-14 2002-02-14 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung

Country Status (8)

Country Link
US (1) US7026304B2 (de)
EP (1) EP1368381B1 (de)
JP (1) JP4313041B2 (de)
AT (1) ATE325135T1 (de)
CA (1) CA2437851C (de)
DE (1) DE60211132T2 (de)
ES (1) ES2261646T3 (de)
WO (1) WO2002064635A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
CA2551826A1 (en) 2003-12-31 2005-07-21 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether .gamma.-cyclodextrin and corticosteroid
EP1730751B1 (de) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Magnetoresistives medium
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
US8054177B2 (en) * 2007-12-04 2011-11-08 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
CN101591402B (zh) * 2009-05-05 2011-11-30 杭州奥默医药技术有限公司 6-脱氧砜类环糊精衍生物及其制备方法
DE102010025818A1 (de) 2010-07-01 2012-01-05 Klaus Jochler Dosiervorrichtung zur Abgabe von Duft-Desinfektions- oder Reinigungsmittel in Speicherbehälter
WO2012061413A2 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
EP3253208B1 (de) 2015-02-02 2021-05-05 MEI Pharma, Inc. Kombinationstherapien zur verwendung bei der behandlung von brustkrebs
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4249282B2 (ja) * 1998-02-27 2009-04-02 日本食品化工株式会社 新規シクロデキストリン誘導体及びその製造方法

Also Published As

Publication number Publication date
DE60211132D1 (de) 2006-06-08
DE60211132T2 (de) 2006-09-28
JP2004526013A (ja) 2004-08-26
US7026304B2 (en) 2006-04-11
WO2002064635A1 (en) 2002-08-22
US20040106575A1 (en) 2004-06-03
JP4313041B2 (ja) 2009-08-12
ES2261646T3 (es) 2006-11-16
EP1368381B1 (de) 2006-05-03
EP1368381A1 (de) 2003-12-10
CA2437851C (en) 2011-05-17
CA2437851A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
ATE325135T1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
DE60234409D1 (de) Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
DE60112974D1 (en) Carbolinderivate
IS1839B (is) Píperasín afleiður sem hafa verkjastillandi áhrif, framleiðsla og notkun þeirra
NO20025590D0 (no) Fenylglycin-derivater
DK1446387T3 (da) Substituerede aryl, 1,4-pyrazinderivater
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE0101932D0 (sv) Pharmaceutical combinations
DE60216233D1 (en) Carbolinderivate
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
HRP20050439B1 (en) New use of dextran sulfate
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
RS52315B (en) DIARYLMETHYL PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
BR0316544A (pt) Compostos calcilìticos
ATE344272T1 (de) Uridinderivate als antibiotika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties